Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -2.7%	$0.19	$0.05 ▼ $1.33	$15.51M	2.18	87.73 million shs	25.99 million shs
ANL Adlai Nortye	$1.67 -1.4%	$1.55	$1.10 ▼ $3.89	$62.36M	-0.95	9,323 shs	1,136 shs
CVM CEL-SCI	$9.52 +3.8%	$5.42	$1.98 ▼ $39.30	$65.52M	0.52	367,351 shs	152,267 shs
GANX Gain Therapeutics	$1.97 +8.8%	$1.68	$0.95 ▼ $3.19	$65.07M	0.1	332,022 shs	467,682 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+2.45%	-19.75%	-78.58%	-79.11%	-95.08%
ANL Adlai Nortye	-0.29%	-3.98%	+8.40%	-8.65%	-43.67%
CVM CEL-SCI	+3.03%	+12.65%	+74.00%	+265.34%	-73.07%
GANX Gain Therapeutics	+4.62%	+17.53%	+11.73%	+0.56%	+34.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.1631 of 5 stars	3.0	3.0	2.9	1.7	0.0
ANL Adlai Nortye	1.7821 of 5 stars	3.0	3.0	3.3	0.0	0.0
CVM CEL-SCI	1.6962 of 5 stars	0.0	4.0	2.7	2.5	0.6
GANX Gain Therapeutics	2.6411 of 5 stars	3.5	3.0	3.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	2,275.51% Upside
ANL Adlai Nortye	2.00	Hold	$9.00	440.22% Upside
CVM CEL-SCI	0.00	N/A	N/A	N/A
GANX Gain Therapeutics	3.00	Buy	$7.80	295.94% Upside

Current Analyst Ratings Breakdown

Latest ADAP, ANL, GANX, and CVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GANX Gain Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/2/2025	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.08	N/A	N/A	($0.27) per share	-0.21
ANL Adlai Nortye	N/A	N/A	N/A	N/A	$0.69 per share	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
GANX Gain Therapeutics	$50K	1,416.43	N/A	N/A	$0.10 per share	19.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.65	N/A	N/A	N/A	-260.82%	-163.73%	-75.83%	N/A
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
CVM CEL-SCI	-$26.92M	-$9.77	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
GANX Gain Therapeutics	-$20.41M	-$0.63	N/A	N/A	N/A	N/A	-289.10%	-155.11%	N/A

Latest ADAP, ANL, GANX, and CVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.15	-$0.11	+$0.04	-$0.11	$11.04 million	$13.68 million
8/12/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	1.52	1.29
ANL Adlai Nortye	0.02	1.41	1.41
CVM CEL-SCI	0.66	1.07	1.09
GANX Gain Therapeutics	0.09	1.79	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ANL Adlai Nortye	35.21%
CVM CEL-SCI	12.08%
GANX Gain Therapeutics	11.97%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
ANL Adlai Nortye	N/A
CVM CEL-SCI	14.06%
GANX Gain Therapeutics	7.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
CVM CEL-SCI	43	6.88 million	64.67 million	Optionable
GANX Gain Therapeutics	20	35.95 million	33.37 million	Optionable

ADAP, ANL, GANX, and CVM Headlines

Recent News About These Companies

Gain Therapeutics Reports Q2 2025 Financial Results

August 21 at 12:10 AM | tipranks.com

Roth Capital Analysts Increase Earnings Estimates for GANX

August 17, 2025 | marketbeat.com

Equities Analysts Offer Predictions for GANX Q3 Earnings

August 17, 2025 | americanbankingnews.com

Roth Capital Lowers Gain Therapeutics (NASDAQ:GANX) Price Target to $6.00

August 15, 2025 | americanbankingnews.com

Gain Therapeutics price target lowered to $6 from $7 at Roth Capital

August 13, 2025 | msn.com

Gain Therapeutics reports Q2 EPS (19c), consensus (17c)

August 12, 2025 | msn.com

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

August 12, 2025 | globenewswire.com

Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Thursday

August 12, 2025 | americanbankingnews.com

Gain Therapeutics (GANX) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

July 24, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Abbott Laboratories (ABT) and ANI Pharmaceuticals (ANIP)

July 19, 2025 | theglobeandmail.com

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

July 16, 2025 | globenewswire.com

Gain Therapeutics stock falls after announcing public offering

July 16, 2025 | uk.investing.com

Gain Therapeutics Announces Proposed Public Offering

July 15, 2025 | globenewswire.com

Gain Therapeutics Inc News (GANX) - Investing.com

July 8, 2025 | investing.com

Gain Therapeutics, Inc. Reports Successful Enrollment in Phase 1b Study of GT-02287 for Parkinson’s Disease

June 30, 2025 | quiverquant.comQ

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

June 30, 2025 | globenewswire.com

Scotiabank Sticks to Its Buy Rating for Gain Therapeutics (GANX)

June 27, 2025 | theglobeandmail.com

Gain Therapeutics to Participate in Upcoming Investor Conferences

June 10, 2025 | globenewswire.com

Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal

May 29, 2025 | quiverquant.comQ

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADAP, ANL, GANX, and CVM Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.06 0.00 (-2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$0.06 +0.00 (+2.11%)

As of 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adlai Nortye NASDAQ:ANL

$1.67 -0.02 (-1.42%)

Closing price 03:57 PM Eastern

Extended Trading

$1.65 -0.02 (-0.96%)

As of 04:04 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

CEL-SCI NYSE:CVM

$9.52 +0.35 (+3.82%)

Closing price 04:00 PM Eastern

Extended Trading

$9.71 +0.19 (+2.00%)

As of 08:00 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Gain Therapeutics NASDAQ:GANX

$1.97 +0.16 (+8.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 -0.03 (-1.52%)

As of 07:42 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time